Technical Analysis for BLUE - bluebird bio, Inc.

Grade Last Price % Change Price Change
grade F 106.08 -1.27% -1.36
BLUE closed down 1.27 percent on Thursday, September 19, 2019, on 62 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical BLUE trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
Weak + Overbought Other 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Overbought Stochastic Strength 0.00%
Weak + Overbought Other -1.27%
Overbought Stochastic Strength -1.27%
1,2,3 Retracement Bearish Bearish Swing Setup -0.60%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.60%
Doji - Bearish? Reversal -0.60%

Older signals for BLUE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology New Jersey Rare Diseases Medical Genetics Celgene Genetic Genealogy Human Diseases Summit
Is BLUE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 5 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 163.425
52 Week Low 87.49
Average Volume 531,888
200-Day Moving Average 127.4413
50-Day Moving Average 118.671
20-Day Moving Average 103.2605
10-Day Moving Average 103.701
Average True Range 4.6259
ADX 35.27
+DI 16.7868
-DI 26.4358
Chandelier Exit (Long, 3 ATRs ) 110.2773
Chandelier Exit (Short, 3 ATRs ) 109.2377
Upper Bollinger Band 109.6274
Lower Bollinger Band 96.8936
Percent B (%b) 0.72
BandWidth 12.331724
MACD Line -3.1019
MACD Signal Line -4.6431
MACD Histogram 1.5412
Fundamentals Value
Market Cap 4.84 Billion
Num Shares 45.6 Million
EPS -7.33
Price-to-Earnings (P/E) Ratio -14.47
Price-to-Sales 233.66
Price-to-Book 5.18
PEG Ratio 0.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 112.58
Resistance 3 (R3) 112.72 110.70 111.49
Resistance 2 (R2) 110.70 109.05 110.63 111.13
Resistance 1 (R1) 108.39 108.02 107.38 108.25 110.77
Pivot Point 106.37 106.37 105.87 106.30 106.37
Support 1 (S1) 104.06 104.72 103.05 103.92 101.39
Support 2 (S2) 102.04 103.69 101.97 101.03
Support 3 (S3) 99.73 102.04 100.67
Support 4 (S4) 99.59